[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Use of Artificial Intelligence in Pharmaceutical Drug Development and Clinical Trials: Case Study

January 2021 | 64 pages | ID: UA623A8AD390EN
GlobalData

US$ 495.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Use of Artificial Intelligence in Pharmaceutical Drug Development and Clinical Trials: Case Study

SUMMARY

The pharmaceutical industry has a reputation as being risk averse to embracing new technologies and spent many years in “watch and wait” mode regarding artificial intelligence (AI). Compared to other industries, pharma has been slow to adopt AI, but there has been increased activity over the past few years. This case study provides an overview of how AI is currently being implemented by the pharmaceutical industry in drug discovery and clinical trials

KEY HIGHLIGHTS
  • Pharma has been slow to adopt AI, but increased activity has been seen since 2019. Pharma also plans to invest in AI in the near future.
  • While COVID-19 may have temporarily shifted investment away from AI, it could actually lead to increased AI adoption.
  • Drug discovery is the area most likely to benefit from AI.
  • Harnessing the benefits of AI requires pharma companies to navigate a series of practical and ethical challenges.
SCOPE

This case study includes -
  • Examples of pharma companies leading the integration of AI into their operations
  • Examples of partnerships between Big Pharma and AI start-ups
  • Examples of other AI initiatives by pharma, including the establishment of in-house capabilities.
  • AI vendor company profiles
REASONS TO BUY
  • Develop business strategies by understanding how AI is being used in the biopharmaceutical industry today and how the technology is expected to affect the sector in the future.
  • Stay up to date on the key players in the AI space in drug development and clinical trials.
  • See what activities biopharmaceutical companies are undertaking in the space.
  • Identify opportunities for partnerships with AI vendors.
Summary
Introduction
Overview of AI
AI and the Pharmaceutical Industry
Examples of Leaders in AI Across the Pharmaceutical Industry
Pharma Plan to Invest in AI in the Next Two Years
AI Recognized as a Leading Disruptive Technology in Pharma
Artificial Intelligence in Drug Discovery
AI has the Potential to Transform Drug Discovery
Pharma Partners with AI Start-Ups, but Are Developing In-House Capabilities
COVID-19 Could Be a Tipping Point for AI Technology
Increasing Number of AI Drug Discovery Partnerships with Big Pharma
Pfizer, Takeda, and AstraZeneca Lead the Way in Drug Discovery Partnerships
Examples of Recent Big Pharma AI Partnerships
Company Profiles and Partnership Examples
BenevolentAI Discovers Lilly’s Olumiant Can be Repurposed for COVID-19
Several Pharma Companies Are Involved in AI Research Consortiums
GSK an Early Pioneer in Setting Up In-House AI Capabilities
GSK Has Recently Established Additional In-House AI Capabilities in the UK
Roche Centre of Excellence Launches to Research AI in Healthcare in Canada
Artificial Intelligence in Clinical Trials
Improving Trial Design
Improving Trial Recruitment
Remote Health Monitoring and Preventing Non-Adherence
Pharma Companies Are Exploring AI Solutions for Clinical Trials
Clinical Research Organizations Are Also Exploring AI Technology to Enhance Clinical Trials
AI can Mitigate the Impact of COVID-19 on Clinical Trial Disruption
Partnership Examples
Key Findings
Appendix
Related Reports
Abbreviations
Bibliography
Our Thematic Research Methodology
About the Authors
Contact Us

COMPANIES MENTIONED

GSK
Novartis
Novartis
Roche
Bayer
Exscientia
Atomwise
Recursion
Iktos
Insilico Medicine
Sensyne Health
BenevolentAI
Deep Lens
Deep 6 AI


More Publications